{"id":375512,"date":"2022-09-21T09:26:23","date_gmt":"2022-09-21T11:26:23","guid":{"rendered":"https:\/\/teknomers.com\/fr\/laction-astrazeneca-fait-du-surplace-lue-approuve-le-medicament-astrazeneca-pour-lasthme-severe\/"},"modified":"2022-09-21T09:26:24","modified_gmt":"2022-09-21T11:26:24","slug":"laction-astrazeneca-fait-du-surplace-lue-approuve-le-medicament-astrazeneca-pour-lasthme-severe","status":"publish","type":"post","link":"https:\/\/teknomers.com\/fr\/laction-astrazeneca-fait-du-surplace-lue-approuve-le-medicament-astrazeneca-pour-lasthme-severe\/","title":{"rendered":"L&#8217;action AstraZeneca fait du surplace: l&#8217;UE approuve le m\u00e9dicament AstraZeneca pour l&#8217;asthme s\u00e9v\u00e8re"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"news-container\">\n<div class=\"dropdown-container-chartflow relative\">\n<div class=\"row\" style=\"padding:10px\">\n<p><h3 class=\"box-headline\" style=\"margin:0px\">partages dans cet article<\/h3>\n<\/p>\n<div class=\"col-xs-2 col-sm-1 pointer\"><\/div>\n<\/div>\n<\/div>\n<p>La soci\u00e9t\u00e9 pharmaceutique anglo-su\u00e9doise a maintenant re\u00e7u une approbation correspondante de l&#8217;Union europ\u00e9enne. <\/p>\n<p> Tezspire est utilis\u00e9 comme traitement d&#8217;entretien compl\u00e9mentaire chez les patients dont la maladie est insuffisamment contr\u00f4l\u00e9e par des corticost\u00e9ro\u00efdes inhal\u00e9s \u00e0 forte dose et d&#8217;autres produits, a d\u00e9clar\u00e9 AstraZeneca. <!-- sh_cad_2 --><\/p>\n<p>  Tezspire a d\u00e9j\u00e0 \u00e9t\u00e9 approuv\u00e9 pour cette indication aux \u00c9tats-Unis, entre autres, et d&#8217;autres pays examinent cela, selon la soci\u00e9t\u00e9. <\/p>\n<p>  \u00ab Tezspire est d\u00e9sormais le premier et le seul m\u00e9dicament biologique approuv\u00e9 en Europe pour les patients souffrant d&#8217;asthme s\u00e9v\u00e8re sans contrainte de ph\u00e9notype ou de biomarqueur \u00bb, a d\u00e9clar\u00e9 Mene Pangalos, responsable de la recherche et du d\u00e9veloppement biopharmaceutiques.<br \/>\n<!-- sh_cad_4 --><\/p>\n<p>Les actions d&#8217;AstraZeneca ont temporairement perdu 0,04% \u00e0 100,72 livres \u00e0 Londres mercredi.\n<\/p>\n<p>  Par Michael Susin <\/p>\n<p>  LONDRES (Dow Jones)<\/p>\n<div class=\"lvgSearchOuter\"><span class=\"font-bold\">Produits \u00e0 effet de levier s\u00e9lectionn\u00e9s sur AstraZeneca PLC<\/span>Avec les knock-outs, les investisseurs sp\u00e9culatifs peuvent participer de mani\u00e8re disproportionn\u00e9e aux mouvements de prix.  S\u00e9lectionnez simplement le levier souhait\u00e9 et nous vous montrerons les produits ouverts appropri\u00e9s sur AstraZeneca PLC<\/p>\n<div class=\"row\">\n<div class=\"col-xs-12\">\n<p>L&#8217;effet de levier doit \u00eatre compris entre 2 et 20<\/p>\n<\/div>\n<\/div>\n<p>Pas de donn\u00e9es<\/p>\n<\/div>\n<p><!--CenterColumn_1--><\/p>\n<div class=\"\">\n<h2 class=\"box-headline\">Plus d&#8217;actualit\u00e9s sur AstraZeneca PLC<\/h2>\n<\/div>\n<p>Cr\u00e9dits image : Oli Scarff\/Getty Images, Michael Vi\/Shutterstock.com<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.finanzen.net\/nachricht\/aktien\/tezspire-astrazeneca-aktie-tritt-auf-der-stelle-eu-erteilt-zulassung-fuer-astrazeneca-medikament-gegen-schweres-asthma-11729395\" rel=\"nofollow noopener\" target=\"_blank\">ttn-fr-28<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>partages dans cet article La soci\u00e9t\u00e9 pharmaceutique anglo-su\u00e9doise a maintenant re\u00e7u une approbation correspondante de l&#8217;Union europ\u00e9enne. Tezspire est utilis\u00e9 comme traitement d&#8217;entretien compl\u00e9mentaire chez les patients dont la maladie est insuffisamment contr\u00f4l\u00e9e par des corticost\u00e9ro\u00efdes inhal\u00e9s \u00e0 forte dose et d&#8217;autres produits, a d\u00e9clar\u00e9 AstraZeneca. Tezspire a d\u00e9j\u00e0 \u00e9t\u00e9 approuv\u00e9 pour cette indication aux [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":375513,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[6844,29913,369,2101,59626,960,27487,185,19744,97256],"class_list":["post-375512","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance","tag-approuve","tag-astrazeneca","tag-fait","tag-laction","tag-lasthme","tag-lue","tag-medicament","tag-pour","tag-severe","tag-surplace"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/375512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/comments?post=375512"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/375512\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media\/375513"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media?parent=375512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/categories?post=375512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/tags?post=375512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}